Endogenous Radionanomedicine: Validation of Therapeutic Potential View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2018-05-26

AUTHORS

Seunggyun Ha , Dong Soo Lee

ABSTRACT

Exosomes have features to be able to promise therapeutic opportunities, which are exosomes-mediated pathogenesis in certain diseases, and thus their inherent therapeutic potential, and again possibility of use of exosomes as drug carriers. There have been increasing interests in this therapeutic potential of exosomes owing to the recent reports in regenerative medicine, tumor management, infection, and organ transplantation. Radionanomedicines i.e. radiolabeled exosomes provide advantages of non-invasive, less toxic, highly penetrable, highly sensitive, and quantification-enabling characteristic of radioactivity for validation of therapeutic potentials of exosomes. Radiolabeled exosomes are expected to allow their theranostic use even in clinical settings. However, there remain the issues to overcome the low yields of exosomes, release of free radioisotope after degradation of exosomes, and yet unveiled dosimetry of therapeutic radiolabeled exosomes. This chapter reviews current evidences of therapeutic applications of exosomes in regenerative medicine and tumor management and discusses radiolabeled exosomes or exosome-mimetic nanovesicles as well as remaining issues in endogenous radionanomedicines regarding the desired therapeutic potentials of radiolabeled or unlabeled exosomes. More... »

PAGES

167-182

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-319-67720-0_9

DOI

http://dx.doi.org/10.1007/978-3-319-67720-0_9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104229759


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, 03080, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, 03080, Seoul, Republic of Korea", 
            "Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, 03080, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ha", 
        "givenName": "Seunggyun", 
        "id": "sg:person.01107464404.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107464404.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Korea Brain Research Institute, Daegu, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.452628.f", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, 03080, Seoul, Republic of Korea", 
            "Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, 03080, Seoul, Republic of Korea", 
            "Korea Brain Research Institute, Daegu, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Dong Soo", 
        "id": "sg:person.015617314175.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015617314175.88"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-05-26", 
    "datePublishedReg": "2018-05-26", 
    "description": "Exosomes have features to be able to promise therapeutic opportunities, which are exosomes-mediated pathogenesis in certain diseases, and thus their inherent therapeutic potential, and again possibility of use of exosomes as drug carriers. There have been increasing interests in this therapeutic potential of exosomes owing to the recent reports in regenerative medicine, tumor management, infection, and organ transplantation. Radionanomedicines i.e. radiolabeled exosomes provide advantages of non-invasive, less toxic, highly penetrable, highly sensitive, and quantification-enabling characteristic of radioactivity for validation of therapeutic potentials of exosomes. Radiolabeled exosomes are expected to allow their theranostic use even in clinical settings. However, there remain the issues to overcome the low yields of exosomes, release of free radioisotope after degradation of exosomes, and yet unveiled dosimetry of therapeutic radiolabeled exosomes. This chapter reviews current evidences of therapeutic applications of exosomes in regenerative medicine and tumor management and discusses radiolabeled exosomes or exosome-mimetic nanovesicles as well as remaining issues in endogenous radionanomedicines regarding the desired therapeutic potentials of radiolabeled or unlabeled exosomes.", 
    "editor": [
      {
        "familyName": "Lee", 
        "givenName": "Dong Soo", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-319-67720-0_9", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-67719-4", 
        "978-3-319-67720-0"
      ], 
      "name": "Radionanomedicine", 
      "type": "Book"
    }, 
    "keywords": [
      "therapeutic potential", 
      "tumor management", 
      "inherent therapeutic potential", 
      "organ transplantation", 
      "current evidence", 
      "therapeutic opportunities", 
      "clinical setting", 
      "exosome-mimetic nanovesicles", 
      "certain diseases", 
      "exosomes", 
      "recent reports", 
      "theranostic use", 
      "therapeutic applications", 
      "regenerative medicine", 
      "medicine", 
      "transplantation", 
      "pathogenesis", 
      "infection", 
      "disease", 
      "management", 
      "report", 
      "drug carriers", 
      "radioactivity", 
      "setting", 
      "use", 
      "release", 
      "evidence", 
      "potential", 
      "nanovesicles", 
      "dosimetry", 
      "validation", 
      "radioisotopes", 
      "i.", 
      "carriers", 
      "features", 
      "possibility of use", 
      "characteristics", 
      "radionanomedicine", 
      "possibility", 
      "issues", 
      "opportunities", 
      "interest", 
      "chapter", 
      "low yield", 
      "advantages", 
      "degradation", 
      "discusses", 
      "applications", 
      "yield"
    ], 
    "name": "Endogenous Radionanomedicine: Validation of Therapeutic Potential", 
    "pagination": "167-182", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104229759"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-319-67720-0_9"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-319-67720-0_9", 
      "https://app.dimensions.ai/details/publication/pub.1104229759"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-12-01T06:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/chapter/chapter_83.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-319-67720-0_9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-67720-0_9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-67720-0_9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-67720-0_9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-67720-0_9'


 

This table displays all metadata directly associated to this object as RDF triples.

121 TRIPLES      22 PREDICATES      72 URIs      65 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-319-67720-0_9 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author Nbc17a76c8d934df29b24e331cfac5300
4 schema:datePublished 2018-05-26
5 schema:datePublishedReg 2018-05-26
6 schema:description Exosomes have features to be able to promise therapeutic opportunities, which are exosomes-mediated pathogenesis in certain diseases, and thus their inherent therapeutic potential, and again possibility of use of exosomes as drug carriers. There have been increasing interests in this therapeutic potential of exosomes owing to the recent reports in regenerative medicine, tumor management, infection, and organ transplantation. Radionanomedicines i.e. radiolabeled exosomes provide advantages of non-invasive, less toxic, highly penetrable, highly sensitive, and quantification-enabling characteristic of radioactivity for validation of therapeutic potentials of exosomes. Radiolabeled exosomes are expected to allow their theranostic use even in clinical settings. However, there remain the issues to overcome the low yields of exosomes, release of free radioisotope after degradation of exosomes, and yet unveiled dosimetry of therapeutic radiolabeled exosomes. This chapter reviews current evidences of therapeutic applications of exosomes in regenerative medicine and tumor management and discusses radiolabeled exosomes or exosome-mimetic nanovesicles as well as remaining issues in endogenous radionanomedicines regarding the desired therapeutic potentials of radiolabeled or unlabeled exosomes.
7 schema:editor N326c5dcc894d487d9cf5cff41de4c1c9
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Nb86b2e09225e434b99b5dd23e8522528
11 schema:keywords advantages
12 applications
13 carriers
14 certain diseases
15 chapter
16 characteristics
17 clinical setting
18 current evidence
19 degradation
20 discusses
21 disease
22 dosimetry
23 drug carriers
24 evidence
25 exosome-mimetic nanovesicles
26 exosomes
27 features
28 i.
29 infection
30 inherent therapeutic potential
31 interest
32 issues
33 low yield
34 management
35 medicine
36 nanovesicles
37 opportunities
38 organ transplantation
39 pathogenesis
40 possibility
41 possibility of use
42 potential
43 radioactivity
44 radioisotopes
45 radionanomedicine
46 recent reports
47 regenerative medicine
48 release
49 report
50 setting
51 theranostic use
52 therapeutic applications
53 therapeutic opportunities
54 therapeutic potential
55 transplantation
56 tumor management
57 use
58 validation
59 yield
60 schema:name Endogenous Radionanomedicine: Validation of Therapeutic Potential
61 schema:pagination 167-182
62 schema:productId Nbcfc5f3df6cd4118b366c0f96e9b160c
63 Nfd26b3e6f27c4f1e871887c9dd108b96
64 schema:publisher N0e729b3dfd064dc48795f749cb84bd06
65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104229759
66 https://doi.org/10.1007/978-3-319-67720-0_9
67 schema:sdDatePublished 2022-12-01T06:55
68 schema:sdLicense https://scigraph.springernature.com/explorer/license/
69 schema:sdPublisher Nc9e3c8a4ec72486eb15a45c44a39a068
70 schema:url https://doi.org/10.1007/978-3-319-67720-0_9
71 sgo:license sg:explorer/license/
72 sgo:sdDataset chapters
73 rdf:type schema:Chapter
74 N0ca635e847e3458995a22de39edec8af rdf:first sg:person.015617314175.88
75 rdf:rest rdf:nil
76 N0e729b3dfd064dc48795f749cb84bd06 schema:name Springer Nature
77 rdf:type schema:Organisation
78 N24d94816d6d04aef9c2b8da0df74cdc3 schema:familyName Lee
79 schema:givenName Dong Soo
80 rdf:type schema:Person
81 N326c5dcc894d487d9cf5cff41de4c1c9 rdf:first N24d94816d6d04aef9c2b8da0df74cdc3
82 rdf:rest rdf:nil
83 Nb86b2e09225e434b99b5dd23e8522528 schema:isbn 978-3-319-67719-4
84 978-3-319-67720-0
85 schema:name Radionanomedicine
86 rdf:type schema:Book
87 Nbc17a76c8d934df29b24e331cfac5300 rdf:first sg:person.01107464404.68
88 rdf:rest N0ca635e847e3458995a22de39edec8af
89 Nbcfc5f3df6cd4118b366c0f96e9b160c schema:name dimensions_id
90 schema:value pub.1104229759
91 rdf:type schema:PropertyValue
92 Nc9e3c8a4ec72486eb15a45c44a39a068 schema:name Springer Nature - SN SciGraph project
93 rdf:type schema:Organization
94 Nfd26b3e6f27c4f1e871887c9dd108b96 schema:name doi
95 schema:value 10.1007/978-3-319-67720-0_9
96 rdf:type schema:PropertyValue
97 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
98 schema:name Medical and Health Sciences
99 rdf:type schema:DefinedTerm
100 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
101 schema:name Immunology
102 rdf:type schema:DefinedTerm
103 sg:person.01107464404.68 schema:affiliation grid-institutes:grid.31501.36
104 schema:familyName Ha
105 schema:givenName Seunggyun
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107464404.68
107 rdf:type schema:Person
108 sg:person.015617314175.88 schema:affiliation grid-institutes:grid.452628.f
109 schema:familyName Lee
110 schema:givenName Dong Soo
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015617314175.88
112 rdf:type schema:Person
113 grid-institutes:grid.31501.36 schema:alternateName Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, 03080, Seoul, Republic of Korea
114 schema:name Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, 03080, Seoul, Republic of Korea
115 Department of Nuclear Medicine, Seoul National University College of Medicine, 03080, Seoul, Republic of Korea
116 rdf:type schema:Organization
117 grid-institutes:grid.452628.f schema:alternateName Korea Brain Research Institute, Daegu, Republic of Korea
118 schema:name Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, 03080, Seoul, Republic of Korea
119 Department of Nuclear Medicine, Seoul National University College of Medicine, 03080, Seoul, Republic of Korea
120 Korea Brain Research Institute, Daegu, Republic of Korea
121 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...